New target identified for pancreatic cancer treatment
Researchers have found a protein to block the growth of cancer stem-like cells as a possible treatment for pancreatic cancer.
Sep 26, 2023
0
58
Researchers have found a protein to block the growth of cancer stem-like cells as a possible treatment for pancreatic cancer.
Sep 26, 2023
0
58
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.
Dec 3, 2019
0
2
Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually ...
Sep 15, 2022
0
114
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
A rapid genetic testing model for patients with advanced prostate cancer can more quickly identify those with "actionable" gene variants eligible for newer targeted therapies, reports a clinical trial in The Journal of Urology.
Mar 29, 2023
0
3
Scientists have identified a gene mutation in the tumours of men with prostate cancer that is linked to very poor survival—and which could be used to pick out patients for more intensive treatment.
May 6, 2019
0
49
Researchers have recommended changes to how cancer patients are treated, after a new UCL-led study discovered that chemotherapy is significantly more effective for some men with advanced prostate cancer than others.
Jun 24, 2022
0
8
Men taking either of the two most common oral medications for advanced prostate cancer who had also undergone hormone therapy to treat their disease were at higher risk of serious metabolic or cardiovascular issues than patients ...
May 25, 2022
0
25
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer. That conclusion comes from a large randomized clinical trial ...
May 2, 2022
0
14